Physician profile
Ben E Owens
NPI 1679569156
$4,991.11
in general payments reported to CMS, 2019-2025
39 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $966 · 2020: $1,099 · 2021: $775 · 2022: $1,080 · 2023: $475 · 2024: $390 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,071.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $791.58 | 2019-2025 | |
| Astellas Pharma US INC | $643.09 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $633.91 | 2021-2025 | |
| Glaxosmithkline, LLC. | $406.60 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $305.62 | 2019-2024 | Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $246.74 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $224.15 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $196.86 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $183.24 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $137.83 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $114.31 | 2019-2020 | |
| Novo Nordisk INC | $102.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $79.15 | 2019-2022 | |
| Amarin Pharma, INC. | $71.73 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.75 | 2020-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Owens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.